These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1160 related articles for article (PubMed ID: 28223168)

  • 1. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival-associated alternative splicing signatures in non-small cell lung cancer.
    Zhao D; Zhang C; Jiang M; Wang Y; Liang Y; Wang L; Qin K; Rehman FU; Zhang X
    Aging (Albany NY); 2020 Apr; 12(7):5878-5893. PubMed ID: 32282333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
    Gao X; Wu Y; Yu W; Li H
    Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
    Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
    Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
    BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.
    Sun F; Yang X; Jin Y; Chen L; Wang L; Shi M; Zhan C; Shi Y; Wang Q
    Mol Med Rep; 2017 Jul; 16(1):609-616. PubMed ID: 28560415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
    Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
    Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma.
    Jiang L; Zhu W; Streicher K; Morehouse C; Brohawn P; Ge X; Dong Z; Yin X; Zhu G; Gu Y; Ranade K; Higgs BW; Yao Y; Huang J
    BMC Cancer; 2014 Feb; 14():131. PubMed ID: 24571613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of 17 mRNAs and a miRNA as an integrated prognostic signature for lung squamous cell carcinoma.
    Zhang J; Bing Z; Yan P; Tian J; Shi X; Wang Y; Yang K
    J Gene Med; 2019 Aug; 21(8):e3105. PubMed ID: 31215090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
    Liu B; Chen Y; Yang J
    Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K; Wu Y
    BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.